Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (*currently amended*) A monoclonal antibody selected from the group consisting of:

(a) a monoclonal antibody Met3 produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-4349; and

(b) a monoclonal antibody Met5 produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-4477,

or an antigen binding fragment ~~or derivative~~ of said antibody.

2-5. ***(canceled)***

6. (*currently amended*) A humanized monoclonal antibody specific for the receptor protein tyrosine kinase Met (Met), or an antigen-binding fragment of said antibody, wherein

(a) the heavy chain and/or light chain variable region of said antibody or fragment, or an antigen binding site of said variable regions, ~~has all the identifying biological or structural characteristics of the corresponding regions or sites~~ are those of the monoclonal antibody of claim 1; and

(b) substantially all the remainder of the humanized monoclonal antibody or fragment is of human origin[[,]]

~~or an antigen binding fragment or derivative of said humanized monoclonal antibody~~.

7. - 8 ***(canceled)***

9. (*currently amended*) A composition comprising the monoclonal antibody[[,]] or fragment ~~or derivative~~ of claim 1.

10-11. ***(canceled)***

12. (*currently amended*) The composition of [[a]] claim 9, further comprising one or more additional antibodies specific for [[a]] Met, or comprising an antigen-binding fragment ~~or derivative~~ of said additional one or more antibodies.

13. (*currently amended*) The composition of claim 9 further comprising one or more antibodies specific for hepatocyte growth factor (HGF), or comprising an antigen-binding fragment ~~or derivative~~ of said one or more HGF-specific antibodies.

14. (*original*) The composition of claim 13 wherein the one or more antibodies specific for HGF is selected from the group consisting of:

(a) a monoclonal antibody produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-3414;

(b) a monoclonal antibody produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-3416;

(c) a monoclonal antibody produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-3413; and

(d) a monoclonal antibody produced by the hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-3412.

15. (*currently amended*) A diagnostically useful composition comprising (a) the monoclonal antibody[[,]] or fragment ~~or derivative~~ of claim 1 which is ~~diagnostically or~~ detectably labeled; and (b) a diagnostically acceptable carrier or excipient.

16. (*currently amended*) A diagnostically useful composition comprising (a) the composition of claim 9 which is ~~diagnostically or~~ detectably labeled; and (b) a diagnostically acceptable carrier or excipient.

17. (*currently amended*) A diagnostically useful composition comprising (a) the composition of claim 12 which is ~~diagnostically or~~ detectably labeled; and (b) a diagnostically acceptable carrier or excipient.

18. (*currently amended*) A diagnostically useful composition comprising (a) the composition of claim 13 which is ~~diagnostically or~~ detectably labeled; and (b) a diagnostically acceptable carrier or excipient.

19. (*currently amended*) The diagnostically useful composition of claim 15 wherein the monoclonal antibody[[,]] or fragment ~~or derivative~~ is labeled with a detectable label selected from the group consisting of a radionuclide, a positron emission tomography (PET)~~PET~~-imageable agent, a magnetic resonance imaging (MRI)~~MRI~~-imageable agent, a fluorescer, a fluorogen, a chromophore, a chromogen, a phosphorescer, a chemiluminescer and a bioluminescer.

20. ***(canceled)***

21. (*currently amended*) The composition of claim 19 wherein the ~~monoclonal antibody, fragment or derivative is labeled with~~ detectable label is a radionuclide.

22. (*original*) The composition of claim 21 wherein said radionuclide is one which is detectable *in vivo*.

23. (*original*) The composition of claim 22 wherein the radionuclide is detectable by radioimmunoscintigraphy.

24. (*original*) The composition of claim 21 wherein the radionuclide is selected from the group consisting of ^{3}H, ^{14}C, ^{35}S, ^{99m}Tc, ^{123}I, ^{125}I, ^{131}I, ^{111}In, ^{97}Ru, ^{67}Ga, ^{68}Ga, ^{72}As, ^{89}Zr and ^{201}Tl.

25. (*original*) The composition of claim 24 wherein the radionuclide is ^{125}I.

26-30. ***(canceled)***

31. (*original*) The composition of claim 19 wherein the detectable label is a fluorescer or fluorogen.

32. (*currently amended*) The composition of claim 31 wherein the fluorescer or fluorogen is selected from the group consisting of fluorescein, rhodamine, dansyl, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde, fluorescamine, a fluorescein derivative, OREGON GREEN™, RHODAMINE GREEN™, RHODOL GREEN™ and TEXAS RED™.

33-34. ***(canceled)***

35. (*currently amended*) The composition of claim 19 wherein said detectable label is bound to the antibody through one or more diethylenetriaminepentaacetic acid (DTPA) residues that are coupled to the antibody or fragment.

36. (*currently amended*) The composition of claim 35 wherein the detectable label is bound to the antibody or fragment through one DTPA residue.

37. (*original*) The composition of claim 35 useful for MRI diagnosis wherein metal atoms are bound to said DTPA residues.

38. (*original*) The composition of claim 37 wherein said metal is selected from the group consisting of gadolinium, manganese, copper, iron, gold and europium.

39. (*original*) The composition of claim 38 wherein said metal is gadolinium.

40-51. ***(canceled)***

52. (*currently amended*) The ~~therapeutic~~ composition of claim 9 ~~51~~ wherein the monoclonal antibody or fragment is labeled with a radionuclide [[is]] selected from the group consisting of ^{47}Sc, ^{67}Cu, ^{90}Y, ^{109}Pd, ~~^{125}I,~~ ~~^{131}I,~~ ^{186}Re, ^{199}Au, ^{211}At, ^{212}Pb and ^{212}Bi.

53-59. ***(canceled)***

60. (*currently amended*) The ~~therapeutic~~ composition of claim 12~~59~~ wherein the monoclonal antibody or fragment is labeled with a the radionuclide [[is]] selected from the group consisting of ^{47}Sc, ^{67}Cu, ^{90}Y, ^{109}Pd, ~~^{125}I,~~ ~~^{131}I,~~ ^{186}Re, ^{188}Re, ^{199}Au, ^{211}At, ^{212}Pb and ^{212}Bi.

61-64. ***(canceled)***

65. (*currently amended*) A kit, comprising:

(a) a labeled first container comprising the antibody[[,]] or fragment ~~or derivative~~ of claim 1;

(b) a labeled second container comprising a diagnostically or pharmaceutically-acceptable carrier or excipient; and

(c) instructions for using the antibody to diagnose~~, prognose,~~ or monitor ~~or treat~~ a cancerous condition or disease ~~a tumor~~ in a subject wherein cancer ~~or tumor~~ cells in said subject are known or suspected to express Met,

wherein the antibody[[,]] or fragment ~~or derivative~~ is effective for diagnosing~~, prognosing,~~ or monitoring ~~or treating~~ said condition or disease, and said labeled container indicates that the antibody can be used for said diagnosing~~, prognosing,~~ or monitoring ~~or treating~~.

66. (*currently amended*) A method for detecting the presence of Met (i) on the surface of a cell, (ii) in a tissue, (iii) in an organ or (iv) in a biological sample, which cell, tissue, organ or sample is suspected of expressing or containing Met, comprising the steps of:

(a) contacting the cell, tissue, organ or sample with the composition of claim 15; and

(b) detecting the presence of the label associated with the cell, tissue, organ or sample.

67-69. ***(canceled)***

70. (*original*) The method of claim 66, wherein the contacting and the detecting are *in vitro*.

71. (*original*) The method of claim 66 wherein the contacting is in vivo and the detecting is *in vitro*.

72. (*original*) The method of claim 66, wherein the contacting and the detecting are *in vivo.*

73-75. ***(canceled)***

76. (*original*) The method of claim 72 wherein said detectable label is a radionuclide

77-79. ***(canceled)***

80. (*original*) The method of claim 76 wherein the radionuclide is selected from the group consisting of ^{3}H, ^{14}C, ^{35}S, ^{99m}Tc, ^{123}I, ^{125}I, ^{131}I, ^{111}In, ^{97}Ru, ^{67}Ga, ^{68}Ga, ^{72}As, ^{89}Zr and ^{201}Tl.

81-83. ***(canceled)***

84. (*currently amended*) The method of claim 76 ~~80~~ wherein said detecting is by radioimmunoscintigraphy.

85-87. ***(canceled)***

88. (*original*) The method of claim 84 wherein the radionuclide is ^{125}I.

89-91. ***(canceled)***

92. (*original*) The method of claim 72, wherein the detectable label is an MRI-imageable agent and the detecting is by MRI.

93-123. ***(canceled)***

124. (*original*) The hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-4349.

125. (*original*) The hybridoma cell line deposited in the American Type Culture Collection under Accession Number PTA-4477.

126. (*new*) The monoclonal antibody of claim 1 wherein the antigen binding fragment is an Fab fragment, an Fab' fragment , an $F(ab')_2$ fragment, an Fv fragment, an scFV fragment, or a diabody.